Preventive Neurology: Brain Care Today to Protect Tomorrow with Dr. Kellyann Niotis, MD
In this episode of the Let's Talk Brain Health Podcast, we welcome Dr. Kellyann Niotis, MD, the world’s first fellowship-trained preventive neurologist, who shares her insights on early detection and risk reduction for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Lewy body dementia.
Dr. Niotis discusses the emerging field of preventive neurology, the role of blood biomarkers and genetic testing, and the importance of lifestyle choices in maintaining brain health.
She also highlights the impact of cholesterol management, sleep studies, and the significance of personalized care approaches.
Join us as we dive into a comprehensive discussion about the future of brain health and the proactive steps we can take today for healthier brains tomorrow.
00:00 Introduction to Dr. Kellyann Niotis, MD
02:47 What is Preventive Neurology?
06:08 The Role of Biomarkers in Early Detection
13:52 Lifestyle Modifications and Brain Health
17:12 Cholesterol and Brain Health
24:15 The Impact of Statins on Cognition
26:05 Underutilized Tools in Brain Health
30:11 Rapid Fire Questions and Final Thoughts
Resources
-
Connect with Kellyann on Instagram @drkellyannniotis
-
Visit her website and learn more about her new clinic on their website
Research
-
Learn more about the research-informed brain health risks mentioned in this episode from the “Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission” Report
-
Read more about Dr. Lisa Misconi’s research on how estrogen receptors are unregulated in perimenopause in this research article
0:02 Welcome to the Let's Talk Brain Health podcast, a public health educational initiative of the virtual Brain Health Center. I'm your host, Doctor Crystal Color, and I'm so glad you're here. On this podcast, I sit down with incredible guests to explore all things brain health and Wellness. Together, we'll talk about how to care for your total brain health, mind, body, and spirit while sharing the latest brain Health Science practical tips and strategies you can use every day. By prioritizing your brain health, you're taking an important step towards living a happier, healthier life. So let's dive in and welcome today's guest. We'd like to welcome Doctor Kellyanne the Otis to the Let's Talk Brain Health podcast. Doctor Neotus is the world's first fellowship trained preventative neurologist specializing in risk reduction for neurodegenerative diseases such as Alzheimer's, Parkinson's, and Lewy body dementia. She completed her neurology training at New York Presbyterian Weill Cornell, where she served as Chief resident and the inaugural McGraw Fellow in Neurology Research, followed by a fellowship and movement disorders at the Icahn School of Medicine at Mount Sinai. She is the founder of preventive neurology practice in New York City and Director of Parkinson's and Lewy Body Dementia Prevention Research at the Institute for Neurodegenerative Diseases in Florida, where her work focuses on early detection and personalized risk reduction strategies. Dr. Niotis is passionate about advancing the field of preventive neurology not only
1:34 through clinical care and research, but also through advocacy for policy change and expanding access to education and treatment. Her expertise has been featured in media outlets such as CNN, and she has received numerous honors and awards recognizing her work. Previously, Doctor Niotis led the preventative neurology program at the Doctor Peter Adias Practice Early Medical and oversaw the nation's first Alzheimer's prevention clinic at Weill Cornell New York Presbyterian, where she launched research initiatives in Parkinson's and Lewy body dementia prevention. Her research has been published in Neurology, Nature, Mental Health, Frontiers and Aging, Neuroscience, Aging and Disease, Movement Disorders, the Journal of Alzheimer's Disease, Alzheimer's and Dementia, and the Journal of the Prevention of Alzheimer's Disease, and she also has presented at national and international conferences.
2:31 Kellyanne, is there any additional information about your background that you'd like to share with our audience? I think you all learned how much of A nerd I am, so maybe to add some character. I'm also an avid scuba diver. I really love the ocean and on side really am passionate about conservation there. And I'm a dog mom to a lovely goldendoodle who's six years old and who is obsessed with ball, so he keeps me really busy. Nice, we're so. Grateful you're here. We are all fellow dog lovers, all three of us. Today we have at least one thread in common and I think for many of us tuning in share the mutual excitement around the brain.
3:12 I think it would be great though after hearing your extensive bio, you've mentioned this buzzword that has probably sparked a lot of our listeners interest. What is a preventative neurologist and what drew you to this emerging field? Yeah, great question. Preventive neurology isn't a fully recognized field yet. The American Academy of Neurology put out a position statement in 2023, Which aims to have preventive neurology being this thriving field by the year 2050. I think we can do more for our patients and we can do more sooner. But just to give you some background, what is preventive neurology?
3:54 It's a field really dedicated to the early detection and early intervention of at risk individuals who are at risk for diseases such as Alzheimer's, Parkinson's, neurodegenerative diseases, but all neurological diseases on a whole. That could be Ms. that can be stroke. The vision is really broad. My particular niche is in neurodegenerative diseases, Alzheimer's, Parkinson's, Lewy body. But again, there's lots of different neurodegenerative or neurological diseases that ought to have a more prevention focused mind. And really what drew me to this space was thinking and seeing patients in the later stages of dementia and a Parkinson's disease and realizing how little options we had for them.
4:42 And seeing this kind of explosion of research, specifically at the time in the space of dementia and how there was more evidence coming out that there are things that we could be doing earlier on in disease to potentially delay or even hopefully prevents their progression. Yet no physicians that I trained with at the time, we're really focused on that. And I was lucky enough to find an amazing mentor, Richard Isaacson, who really showed me a new way towards prevention and learn so much from him and only continue to bring that work to other diseases like Parkinson's and Lewy Body. You've worked with some of the most forward thinking brain health clinics and you still are continuing that work now. How is this shaped your current approach to care that you'd like to highlight for us today?
5:30 Yeah, I never stopped learning. Pretty much feel like I'm a continuous student even now. I'm always learning, but I've been fortunate enough to have amazing mentors, like I mentioned, Richard Isaacson, Peter Tia is another amazing mentor. A lot of my mentors happened to be men, which I feel very fortunate enough because they really did elevate and showed me a way towards prevention that I never thought about. But as a woman, I have other interests that maybe don't always align with those of the opposite sex. I've been able to gain my understanding of prevention through them, but then also bring this lens of female health and what that means and how women may be disproportionately impacted by some of these diseases. And how our care has to differ based not just on factors like people's genetics, but also their biological sex. Getting into genetics or these new diagnostic tests that are starting to come to market and there's a lot of research going on in the different neurodegenerate diseases. What have you seen about the blood biomarker test and how do you think they're going to be implemented in the coming years for the different neurodegenerate diseases as screening tools?
6:44 1st, I'm beyond excited because it's been a long time coming. We haven't had objective outcome measures to monitor disease progression in any real meaningful way that was easily accessible and not invasive and cost effective. But I think these biomarkers will really pave the way for the future of preventive neurology, not only allowing us to identify disease earlier, but also allowing us to identify who may be at risk earlier and then hopefully allow us to monitor the efficacy of the interventions that we're saving people. A lot of the research in prevention has been criticized because it's so difficult to show that you've actually done something to underlying disease progression for diseases that form over years and decades, having some sort of objective outcome measures going to improve clinical trials, give more evidence for prevention, but also better personalized care.
7:44 My word of caution is that these new emerging tools are available and new ones are coming out regularly. But what I think is really important to emphasize is that these biomarkers have been studied in people who have clinical symptoms, not in at risk or asymptomatic individuals. We haven't yet identified what a normal range is for people who don't have cognitive symptoms, and we don't really understand how dynamic these biomarkers are, how variable they can be based on the time of day, based on if someone exercised that morning.
8:25 A lot of the research that we're doing at the Institute of Neurodegenerative Disease is on that because we're of course interested in learning how these biomarkers change with disease and affected people. But it's also really important to understand people who are at risk, whether that's just family history or genetics, and understand how these biomarkers may present differently in different people and what they mean for that individual. One really cool thing, just to nerd out for a second that we found, and we need more for this puzzle, but I'm just excited to talk about it, is that Tau levels actually seem to fluctuate on a monthly basis based on women's menstrual cycle. And that's actually super important to know because the time of someone cycle that we're testing these biomarkers may really change what we think about or how we interpret the results. We have so much to learn.
9:16 They're not ready for prime time yet, but they are going to be in the future. I really believe that. How do you use these blood biomarker tools to detect risk for early interventions given that what you just said, for example, 34 year old patient comes in the worried I have a concern because mom or dad has a dementia or maybe it's not characterized well in an asymptomatic young person who has a concern about these things? 1 I try to stay away from the term worried because everyone's at risk. Everyone with the brain is at risk. I appreciate that they're being proactive about their care, but you make a really interesting and important point, which is that if we start collecting a ton of data, there'll be a lot of noise.
10:03 And how do we sort through that noise? These tools have to be used appropriately in the right clinical context. Like I mentioned, we are studying them in 34 year olds and 40 year olds and so forth in our research cohort. But more practically speaking, if someone comes in to me and they're really overall healthy and I take a family history and their family members didn't have disease until their 70s or 80s, then the likelihood that we're going to detect an abnormal biomarker finding in a 32 year old is pretty low. That said, it may and in the future turn out to be really valuable to establish a baseline, just like we established baselines for other tests like cholesterol panels. And then we can see how that individuals might change over time and if they start entering more of a risk range. I think the future is a little uncertain, but I can see a lot of potential to use these tools and young people, middle-aged people and older people.
11:02 And getting to the same point about precision medicine or individualized personal diagnostics or baseline following a patient, besides the blood biomarkers that are being studied, does your institute use any digital tools right now as baseline other than what typically is done like the Montreal Cognitive assessment or some other type of more sophisticated neuropsychological assessment, Any type of short tools rather than these very complicated, sometimes complex and very multi hour assessments? Or are you referring to things like vocal analysis and so forth? Yeah. So vocal analysis, exactly.
11:43 There's some AI tools that are available and there's some other digital AI tools that are available. There's a couple startups in the northeastern part of the United States that are interested in this area. Are you all using any of those? We aren't using them. And that's because, to be honest, I don't feel like I need a tool to tell me who's at risk. I know based on my clinical assessment who's at risk. And the question for me is not, is this person at risk or not? It's what are we going to do about it once we find out that they're at risk? While I think a lot of these new emerging diagnostics help in terms of early identification, for me, where the bottleneck is not in identifying the risk of these people, it's getting them the treatment that they need. There's a large group of potentially asymptomatic patients that are preclinical and whether these tools are going to pick up something they're not even aware of Whether you're using that besides saying, yes, you're at risk because of family history, for example, or you have faulty lifestyle that needs to be adjusted. Because we know that untreated hypertension for the controlled diabetes, obesity and all those other conditions are already going to put you at higher risk, regardless of whether you have a family history.
12:57 There's a lot of different AI models that are integrating both MRI data, like you said, vocal data, biomarker data, and giving people scores of who's at risk. I can see the utility in that, but I personally don't find that particularly valuable right now. I do think the biomarkers are extremely valuable, but like I said, we don't understand what a normal threshold is yet. We need a lot more research there. I suspect that a lot of your conversations focus in on the research that's probably caught a lot of our listeners interest. And you can pick up probably any study or news line article now that will tell you, you can mitigate your risk of X lifestyle risk factor by X number of percentage if you focus on a whole laundry list of risk factors.
13:47 And you know, we're always growing more and understanding of the X leads to the Y when it comes to brain health. I'm excited to dive into with you today, Kelly. And we're going to focus on one risk factor in particular that I don't think we have really explored yet on the podcast today in terms of cholesterol. But before we do that, would you like to give us this overall view of how much can people actually control through their lifestyle modifications, especially for those that may have pre genetic disposition for Alzheimer's disease? What is this inspiration or hope and why do you spend so much time talking with people about lifestyle risk factors to mitigate risk in general for neurodegenerative? Diseases.
14:30 Great question and I wish that I had a perfect answer for that. I would be lying if I could say that I knew exactly X amount was preventable due to lifestyle, due to medical comorbidities, but I really don't The best data that we have of course is The Lancet Commission report which says that at least 45% of dementia cases is preventable. That's not including Parkinson's disease. There's definitely less out there on Parkinson's prevention, although more studies are coming out. They're identifying risk factors. Of course we understand traumatic brain injuries. Modifiable social isolation could be risk factors for both. They share a lot in common. I think the 45% of dementia cases being preventable is probably an underestimate. I think there are a lot of risk factors that are fully addressed by The Lancet Commission's report. More than half of dementia cases are preventable. I believe that I fully empower patients to take control of their brain health as soon as possible. Yeah.
15:32 And I think for people that may have followed along in recent years, it's the number of Atlantic Commission reports of preventable cases keeps climbing as well as the risk factors. Do we add a couple more each time? Because we finally say after reviewing the scientific literature of we feel confident enough that there is enough evidence from all of these research studies when we pull them together to say yes. And social isolation was a risk factor that's recently come online. Hearing loss. Even though most clinicians, I think would have agreed, like we could have told you this a while ago, but it was we had enough research across the board when we pulled these data from all across the world as well to eliminate some of those risk factors. I like to think the next couple years when The Lancet Commission reconvenes, that number may still go up.
16:17 But speaking with experts like yourself, 2 neurologists at see and treat many patients at Cutting Edge Institute, we have this confidence now that yes, there is likely still going to be more that we know and uncover as well as sums that don't always make that list because we're really split on things like nutrition. I'd suspect you spend a lot of your time talking about nutrition, but to get enough evidence where we're going to globally agree, I don't know, we may have to agree to disagree on some of those. And same things with sleep. I sure you spend a lot of time. I always joke with people when we do education, it's like, here's the scientific evidence of the Atlanta Commission report, and then here's also a long list of risk factors that still have enough evidence behind that.
17:00 Who knows if we're going to consensus on anytime soon. But I guarantee if you talk with your healthcare providers, they're not overlooking these big ones. And they are likely on those screens that you go down your laundry list for. And we know with heart health, cholesterol is a big one. That's the one that many people have the connection with is heart health and brain health. But can you tell us why that's so important of a risk factor that you want to highlight for us today? And what should our listeners know about that risk factor? Yeah, this is one of my favorite risk factors because I'm also, underneath all of this, a lipid nerd. I didn't intend to become a lipid nerd, but my path is crossed with an amazing lipidologist.
17:41 Doctor Tom Dayspring really taught me so much about peripheral lipidology. And when I kept asking questions about brain lipidology, he had no choice but to start diving deeper in the literature with me. We really started learning about this together and it really blows my mind how many neurologists don't understand that the lipid system in the brain is completely distinct from the peripheral lipid system and that one of the most significant genetic risk factors for Alzheimer's disease, which is APOE, is a lipid transport gene. The thought that cholesterol isn't somehow related to brain health is really wild. Doctor Alzheimer's realized this when he did autopsies on Alzheimer's patients when he was first described describing the disease, how there were these little lipid droplets stuck inside the astrocytes of patients that were affected by this.
18:38 The reason I want to highlight this is because so many people carry this high risk gene a Bowie and those people a Bowie four and those people who carry a Bowie 4 have known higher risk of cardiovascular disease, atherosclerotic disease, heart attack, but also higher risk of stroke and also higher risk of neurodegenerative diseases like Alzheimer's and Lewy body. And a lot of that has to do with peripheral cholesterol transport. We understand these people are more likely to throw down atherogenic LDL or APO B particles to cause blockages in the vessels that lead to the brain and inside the brain. But also APOE 4 changes the way that the brain transports cholesterol.
19:24 People who carry this APOE 4 gene are not as efficient at getting cholesterol between brain cells, between astrocytes and neurons, and the cholesterol gets stuck inside these astrocytes and can cause a lot of neurotoxicity and cytotoxicity. And this is one way that APOE 4, for example, can lead to neurodegenerative diseases. It is a sore subject for me because a lot of patients will come in and they'll say my cholesterol numbers all look great. And I look at them and I'm like, who said that these look great? For what do these look great? If we're in the business of preventing disease, then we can't let you walk around in your 30s and 40s with.
20:07 An apo B level of nearly 100 or an LDL cholesterol of nearly 100, It's just a matter of time before that's going to start causing issues for the heart, but also for the brain. I think there's a lot of fear amongst patients in terms of getting their cholesterol treated and the thought of them being on a medication for the rest of their life can be a little overwhelming. But I really, and I would hope that the listeners here today are taking away this message that we can be equal opportunists and sometimes because of our genetics, we need medications. And these medications can be wildly helpful. And the earlier that we start addressing this risk factor, the better. That was my question for you was for the person that's hesitant because this seems to be a lifestyle risk factor that can actually present very early in life. Because I look back to even being an undergrad when having peers have this first factor come on in our late teens and early 20s.
21:06 And that can be a very quick barrier that comes up because this is a very atypical thing. But yet when you have a genetic predisposition, that's not actually that uncommon at times. And yet that can be 1 where we become very resistant. And also it happened to the ones that were like athletes. I remember college athletes that ran track that see the nutritionists that are doing the lifestyle things, and it becomes that conversation of where does the interplay of lifestyle and genetics almost come online? And it was very strange, right? You're late teen and you're in your early 20s, and we never heard of anybody with high cholesterol, let alone taking up medication for it. I remember that was like one of the first things where it just sounds so atypical and then let you think when that Fast forward down the lifespan level of awareness that could be. Yeah, absolutely.
21:59 And it's not to dismiss diet. I've been humbled by people who have come to me and have said no, I'm going to do a complete overhaul on my diet and then we'll recheck my cholesterol levels. Diet can move the needle and especially for people who carry the safe OE 4 gene because they tend to absorb more cholesterol from their food. It's part of what this gene does. They actually do have a pretty dramatic response to reducing things like saturated fats. But at the end of the day, sometimes we're up against our genetics and we have no no other choice. And no matter how well we live our life and how great we eat and how much we're sleeping and exercising, sometimes we just need a medication and.
22:42 It seems like this is the great time to have that lifestyle conversations with your providers to find what your options are, to find your threshold for change, of where you're willing to try and where does lifestyle meet medication opportunities really to support where you are today and where your goals are to be. I think this is the great chance of many times where provider education can be really important, as well as noticing yourselves where your threshold is and where you can try and how far you're able to go. And that might be the balance of where you work with your healthcare providers, where health coaches might come online and other supports that you have on your healthcare team. But great resources to lean in on go back to you as well as any final messages for people on this particular lifestyle risk factor that you want to highlight before we dive into the next topic area with you in. Job.
23:34 I just think the earlier the better. You're never too young to get a full lab test done which includes metabolic tests, lipid tests, nutritional tests. You just never know until you start doing the testing what might be a risk factor for you. And if this flags on your panel then I would not ignore it. So if you have all that on your annual screen, I believe cholesterol is one that's pretty normal on those annual screens to make sure to to your provider about it, because now you've heard it here or at least you got a little bit more extra education on even if it's that higher norm of you still want to follow up with your providers. Kellyanne, there's been an ongoing belief system in the public that statins are bad, that they can cause cognitive issues. What is the up to date?
24:20 You know that in taking it to statin groups can negatively affect cognition. Yeah, good question. Unfortunately we don't have the best quality studies in this space. Most of the evidence seems to point to statins being overall good and protective for brain health and lower risk for dementia. But again, there's no one-size-fits-all. It is true that certain people who get on statins have brain fog. They feel they have an attention slower processing. That's a fact. It's a known risk factor side effect of statin use. Maybe it happens in 5% or less of people. If that happens to you, it's probably related to the fact that the statins can cross through the blood brain barrier and change cholesterol production or suppress cholesterol production in the brain.
25:07 And cholesterol is an important molecule or brain needs cholesterol for lots of other things like neurotransmitter synthesis and cell membrane health and fluidity. While that effect of statins, meaning they're effective suppressing or reducing production of cholesterol everywhere in the brain included might actually be desirable in some people, it might not be in other people. And we really wouldn't know that until we put someone on it. And I would love to say that we're going to have an amazing clinical trial that's going to give us the answers. But statins are so cheap. There's very little incentive to run such a beautiful clinical trial that's going to last decades to really test whether statins are associated with a lower risk of dementia. My practice is no one-size-fits-all. It might work for somebody, but it might not work for somebody else.
25:55 Thanks. I was going to lead into this next section because I know you could probably talk about each one of these for 1/2 an hour. So I'll make it very brief. And I was thinking about my own answer to this question, but obviously I'm going to let you say what you think. Are there particular tools that are still underutilized in mainstream healthcare that can make a big difference in prevention of brain deterioration, memory thinking problems? Good question. The first thing that came to my mind is actually sleep studies. This is not added to The Lancet Commission's list yet, but it's hard for me to believe that sleep apnea won't be added to the list of modifiable risk factors. I think that's huge for brain health.
26:35 You're depriving your brain of oxygen during sleep. Like how could that not be a problem? And I really think sleep apnea is under diagnosed. There are now ways that we can do simple at home sleep studies. And the argument is always from clinicians that they're not as good as sleep studies that are done in sleep labs. But those aren't that practical for people. I think we have now cool screening tools that we can send people home with and do an at home sleep study and get a good read on one night. It might not be a perfect test, and if you have a high clinical suspicion you might want to do more extensive testing, but I think it's a really cheap and underutilized tool. What do you think about owning a blood pressure monitor? I think it's really smart to have a blood pressure cuff at home.
27:17 When we go into the doctor's office, the chance that we're a little excited and maybe anxious about the visit is high. The chance we may get a high reading is not uncommon. I find that it's better to get patients in their home and their comfortable environment and have them do about a week long blood pressure log just so we can see what the variability in their blood pressure recordings are and really determine is blood pressure an issue for this person and if so, we should maybe think about it earlier rather than later. So this add on question about. So there's a series of tests, some of them are commonly done by primary care providers such as hemoglobin A1C or fasting blood sugars, lipid checks, the standardized tests, maybe even vitamin deficiencies, B12, thyroid tests. How do you help?
28:05 Like the patient comes to your specialized clinic and they may have already seen a primary care provider. I presume most of these tests have already been done, but how do you prioritize which tests are the most valuable for a person's personal risk profile? I presume most of it's historical and just there's certain tests that are typically done on somebody who has a concern, but now we're dealing with maybe somebody who may have symptoms. That's where I'm thinking about the asymptomatic patient who's concerned about their brain health in terms of the testing to do, routine blood testing and things like that. I think that everyone should have those basic things checked, and they probably have had them checked with their primary care doctor, but their primary care doctor, because they're the guardian of every other organ system, they can't be the guardian of the brain. So us neurologists have to be the guardian of the brain. And that means that we have to go to the basement of the brain sometimes and help weigh in on risk factors that affect what's happening outside the brain.
29:05 All of these things that you mentioned like metabolic screenings, nutritional screenings, maybe even hormonal screens for the right person can be informative to someone's risk. What I do in my practice and many ways to do this is I really look to the person's family history, ask them about their family member who is affected by whatever disease, Alzheimer's, Parkinson's, whatever it was, and really try to understand their family history and try to figure out what potential things in their family history led to their disease. Did they have high cholesterol? Were they overweight? Did they have diabetes? Like those are clues for the individual that's sitting in front of you. What could it be potentially driving their risk? Great answer by a neurologist.
29:51 Thank you. Don't know how our time went by so quickly, but we're getting to the end of our conversation and we like to make sure we get to give our listeners some rapid takeaways from their brilliant brain. Kellyanne. So some surprise questions because we know the brain love, novelty and challenge and probably a little bit of a challenge for you because you were a self-proclaimed brain nerd. I'm sure people already saw your bio, but we're going to see how you do. OK. One book or a possibly Seminole research study that shifted your thinking on brain health that you'd like to share with our audience today. Oh, OK, great question.
30:31 I'm going to go with a mentor of mine, Lisa Moscone. While I was working with her at Weill Cornell, she was working on estrogen scans and following women through perimenopause and menopause. And she published amazing work. And if you haven't checked it out, I'm a huge fan of hers showing how the brain going through menopause actually up regulates estrogen receptors, which is something we thought, wait, how? But it's like the brain's effort to try to suck in as much of the remaining estrogen from the blood as possible because estrogen so neuroprotective. When I first started down the prevention path, I recognize that there was this difference between men and women in terms of men being at higher risk for Parkinson's, women being at higher risk for Alzheimer's. But how do you wrap your head around that? And there's probably so many avenues to explain that. But because hormone replacement therapy for women has been so shut out, the work of people like Doctor Moscone who are showing us that, hey, hormones are important for brain health, something's happening in our brains during mid, mid life or later in life related to hormonal shifts. That's really changed the way that I think about hormones and really why I integrate them so heavily in my practice. We will include a link to that research in her book in the show notes below so people can find that. As a preventative neurologist, what is your one non negotiable for caring for your own
32:02 brilliant brain? I love it. So movement. I try to do something active every single day. It doesn't have to be intense, it just has to be consistent. We all do a lot of desk work, so I try my best to get up and walk around as much as possible if I'm not able to exercise that day. How can our listeners find out more about you or follow your own work? Oh, great question. You can see my Instagram, I post pretty regularly on there. I'm a science nerd, so a lot of the content that I post is just about new research in the space. If you like higher touch, less maybe accessible content than follow me.
32:43 Although I do try to give some super helpful tips for the everyday person. That's Doctor Kellyanne Niotes on Instagram and then my website, which is www.drkellyanneiotis. And coming in October, we'll have our new practice website fully launched, which will be preventiveneuro.com. And we will include links to all those below in the show notes. And yes, you do provide wonderful informative videos. So I encourage all of our listeners to be sure to check those out. I wasn't sure you have the final last word with our listeners. What's the key message you hope they have from our conversation today as the take away? The take away for me always is that it's never too late to start caring about your brain health. A lot of people worry that they're in their 60s or 70s and there's nothing that they can do anymore, but I just don't believe that's true.
33:36 So never too early, and definitely never too late to start caring. We hope today's conversation highlights a powerful shift and how we approach brain health, one that's rooted in early detection, personalized care, and a belief that prevention is possible. It's clear that brain health isn't something we should wait to think about. It's something we can take action on today. Doctor Niotes, it reminds us that neurodegenerative diseases often begin developing decades before symptoms appear, which means prevention truly starts now, not later. The future of neurology isn't just about treating disease. It's about protecting and optimizing the brain long before symptoms start.
34:16 Doctor Kellyanne Niotis, thank you so much for letting us pick your brilliant brain on the Let's Talk Brain Health podcast. Thank you for investing your time and energy into your personal brain care by listening to today's episode of the Let's Talk Brain Health Podcast. I hope our conversation gave you fresh insights, a bit of inspiration, or practical steps that you can take on your own personal brain care journey. If you enjoyed today's conversation, I'd like to ask you to please share this episode with someone who could benefit from it or consider leaving us a review. If you have questions or a topic in brain health you'd like me to explore, please e-mail me anytime at podcast at virtualbrainhealthcenter.com. I'd love to hear from you.
35:02 We have so many more exciting topics ahead, and I can't wait to continue this lifelong journey of better brain health together with you and our growing virtual community. Until next time, remember to give your brain the care it deserves and make your brain health a priority.
Preventive Neurologist
Dr. Kellyann Niotis is the world’s first fellowship-trained preventive neurologist, specializing in risk reduction for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Lewy Body Dementia. She completed her neurology training at NewYork-Presbyterian/Weill Cornell, where she served as Chief Resident and the inaugural McGraw Fellow in Neurology Research, followed by a fellowship in movement disorders at the Icahn School of Medicine at Mount Sinai.
She is the founder of Preventive Neurology Practice in New York City and Director of Parkinson’s and Lewy Body Dementia Prevention Research at the Institute for Neurodegenerative Diseases (IND) in Florida, where her work focuses on early detection and personalized risk reduction strategies.
Dr. Niotis is passionate about advancing the field of preventive neurology—not only through clinical care and research but also through advocacy for policy change and expanding access to education and treatment. Her expertise has been featured in media outlets such as CNN, and she has received numerous honors and awards recognizing her work.
Previously, Dr. Niotis led the preventive neurology program at Dr. Peter Attia’s practice, Early Medical, and oversaw the nation’s first Alzheimer’s Prevention Clinic at Weill Cornell/NewYork-Presbyterian, where she launched research initiatives in Parkinson’s and Lewy Body Dementia prevention. Her research has been published in Neurology, Nature Mental Health, Frontiers in Aging Neuroscience, Aging & Disease, Movement Disorders, Journal of Alzheimer’s Disease, Alzheimer’s &… Read More
Apple Podcasts
Spotify
Amazon Music
RSS Feed